Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:31:54.822Z.
Calculation as of: 2026-10-06T18:31:54.822Z.
Quote observation: 2026-10-06T18:29:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a4a1852cf81cc3bdb1e5d7e5b94f2a11abdcd35c6fdd639146ba2a4a55dbff9
PE RATIO
N/A
Market Cap
$1.43M
PE Ratio
N/A
TTM Avg
21295.08
3Y Avg
21295.08
5Y Avg
21295.08
Market Cap
$1.49M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jupiter Neurosciences, Inc. (JUNS) | $1.39M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| INVO Fertility, Inc. (IVF)vs › | $1.43M | N/A | 21295.08 | 21295.08 | 21295.08 |
| NEXGEL, Inc. (NXGL)vs › | $1.43M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.43M | N/A | 47.01 | 47.01 | 34.74 |
| NewcelX Ltd. (NCEL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.48M | N/A | N/A | N/A | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.49M | N/A | N/A | N/A | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.60M | N/A | 4.04 | 4.04 | 4.04 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.87
Forward EPS (Est.)
$4.50
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
